Aduro Biotech (ADRO) Tops Q3 EPS Views; Receives EMA Orphan Drug Designation for CRS-207

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. NVDA
6. WYFI
7. STUB
8. EAT
9. BTGO
10. GO

Go back to Aduro Biotech (ADRO) Tops Q3 EPS Views; Receives EMA Orphan Drug Designation for CRS-207
(NASDAQ: ADRO) Delayed: 14.60 --0 (-0%)
Previous Close $14.60    52 Week High $34.95 
Open $0.04    52 Week Low $7.26 
Day High $14.60    P/E N/A 
Day Low $14.60    EPS $0.00 
Volume 250